Current Issue : October-December Volume : 2026 Issue Number : 4 Articles : 8 Articles
Acute kidney injury (AKI) complicates pharmaceutical treatment because decreased renal clearance, drug distribution and uncertain renal recovery can all enhance toxicity or jeopardize therapeutic effectiveness. Traditional dose adjustments based on isolated serum creatinine measurements may be insufficient because creatinine kinetics lag behind changes in renal function. This review suggests a dynamic, pharmacist-led approach for customized drug treatment as AKI progresses and recovers. The framework includes medication reconciliation, serial renal function testing, urine output, fluid balance, hemodynamic state and kidney replacement therapy requirements. Pharmacists can detect nephrotoxic exposures, determine whether treatment is necessary, prioritize medication-related risks, optimize dose regimens and assist with therapeutic drug monitoring. Antimicrobial stewardship and review of high-risk medications are critical to avoiding overexposure and inadvertent undertreatment. Structured communication, documentation and specific review triggers can improve collaboration between pharmacists, prescribers and nephrologists. Electronic clinical decision-support systems may enable prompt intervention, but their usefulness is dependent on data quality, workflow integration and clinical interpretation. Medication review is also required during care transitions to ensure that temporary dose reductions and medication holds are evaluated and important therapies are properly resumed. Individual medication-safety treatments have shown promise, but the efficacy of an integrated, trajectory-guided pharmacist-led framework has yet to be proven. To determine the feasibility and clinical utility of the framework, prospective multicentre studies should assess medication appropriateness, preventable adverse drug events, treatment effectiveness, resource utilization and patient-centered outcomes....
CAR-T cell therapy has emerged as an important therapeutic advancement in the management of relapsed or refractory haematological malignancies. However, treatment-associated immune dysfunction, prolonged cytopenias, B-cell aplasia, hypogammaglobulinemia and immunosuppressive therapy increase the risk of bacterial, viral and fungal infections. Antimicrobial prophylaxis plays a crucial role in infection prevention; nevertheless, variations in immune recovery and infection susceptibility make fixed-duration prophylactic strategies challenging. Prolonged antimicrobial exposure may also contribute to drug-related toxicities, drug interactions, antimicrobial resistance and disruption of the gut microbiome. This review examines the evolving landscape of infectious complications following CD19- and BCMA-directed CAR-T cell therapy, focusing on immune dysfunction, prophylactic antimicrobial strategies, infection-risk assessment and antimicrobial-associated medication-related challenges. Particular emphasis is placed on the clinical pharmacist's role in antimicrobial prescription review, dose optimisation, toxicity surveillance, drug interaction management and multidisciplinary collaboration. Furthermore, an integrated dynamic, pharmacist-led antimicrobial stewardship framework is proposed, incorporating baseline infection-risk assessment, longitudinal immune monitoring, antimicrobial optimisation and individualised prophylaxis continuation, modification or discontinuation. The proposed approach considers absolute neutrophil count, CD4+ T-cell recovery, immunoglobulin levels, infection history and immunosuppressive exposure to support informed clinical decisions. By integrating immune recovery with medication safety and antimicrobial stewardship, this framework may promote appropriate prophylaxis, minimise unnecessary antimicrobial exposure and improve supportive care. Prospective multicentre studies are required to validate its clinical applicability and determine its impact on infectious complications and patient outcomes....
The mainstay of treatment for colorectal cancer (CRC) is chemotherapy, however side effects can lower quality of life, lead to unscheduled medical visits and interfere with drug administration. Through medication reconciliation, regimen-specific risk assessment, patient education, supportive care review, symptom monitoring and pharmacovigilance, clinical pharmacists can promote safer treatment. This narrative review summarizes research on the management, early identification and prevention of significant toxicities linked to irinotecan, oxaliplatin and fluoropyrimidines. Additionally, it takes into account patient-reported symptoms, pharmacogenetic risk assessment and the differentiation between clinical interventions recommended by guidelines and results attributed to services provided by pharmacists. Although demographics and outcome metrics are diverse and there is still no direct data specific to colorectal cancer, evidence from oncology pharmacy research suggests benefits for medication-related procedures. Pretreatment evaluation, cycle-based monitoring, triage and intervention, documentation and pharmacovigilance and reassessment comprise the five stages of the suggested closed-loop practice framework. Review completion, medication-related issue resolution, severe toxicity, urgent care use, treatment change and patient-reported symptom burden are all recommended evaluation metrics. The framework is a suggested practice model rather than a proven intervention; in order to determine its viability, resource needs and clinical efficacy, prospective study is necessary....
In older persons with colorectal cancer (CRC), frailty is a multifaceted state of decreased physiological reserve that can impact recovery, quality of life and treatment tolerance. The evidence on frailty assessment and CRC outcomes is summarized in this narrative review, with a focus on pharmacy-practice interventions that can convert evaluation into safer, more customized care. Although results vary by instrument, demographic and treatment environment, there is evidence linking frailty to postoperative morbidity, therapeutic toxicity, inadequate therapy, functional decline and lower survival. Medication burden, comorbidities, nutrition, cognition, function and social support needs can all be identified by a thorough geriatric evaluation. Medication reconciliation, screening for potentially inappropriate medications and interactions, organ-function-related dosage review, adherence support, toxicity education and communication with the multidisciplinary team are some ways pharmacists can help. There is encouraging evidence for pharmacist-led medication optimization in geriatric oncology, although it is not CRC-specific and is still scarce. While biomarkers, digital phenotyping and artificial intelligence are still under investigation, prehabilitation, sarcopenia assessment and long-term monitoring may enhance therapy. Oncological judgment and collaborative decision-making should be complemented, not replaced, by frailty-informed pharmacological care....
Medication errors are an issue within healthcare that cause preventable damage to patients, resulting in increased admissions, treatment issues and costs. These can occur at any point of the medication pathway. This review will focus on the types, causes, prevalence and impact of medication errors. It will also highlight innovations in prevention and how clinical pharmacists contribute to drug safety. A summary of the existing evidence and practice was identified by reviewing literature regarding drug errors, patient safety, clinical pharmacy services and innovations. Key contributing factors have been identified including communication issues, time pressure, lack of training, complex medication regimes and system failures. Prevention strategies such as automated dispensing systems, barcode medication administration, electronic prescribing, clinical decision support systems, medication reconciliation and standardized medication regimes are also discussed. Clinical pharmacists play a significant role in medication safety through prescription checking, medication reviews, patient advice, pharmacovigilance, identification and prevention of drug related problems and working within multi-disciplinary healthcare teams. Innovations such as artificial intelligence, predictive analytics and smart infusion devices are exciting new technologies that provide further opportunities to increase drug safety. A combination of innovations, effective reporting systems, continued professional development and clinical pharmacist involvement are required to reduce prescription errors and improve safer and efficient patient care....
Globally, type 2 diabetes mellitus (T2DM) is a chronic metabolic disease that is spreading quickly and has significant clinical, financial and social costs. Medication non-adherence, drug-related problems (DRPs), adverse drug responses, polypharmacy and complex therapy regimens make it difficult to achieve adequate glycemic control even with the availability of effective pharmacological interventions. These difficulties often impair the efficacy of treatment, raise healthcare costs and hasten the onset of problems associated with diabetes. With active pharmacist involvement, pharmaceutical care has become a patient-centered practice approach that aims to maximize medication use and enhance therapeutic results. With a focus on medication adherence, DRP detection and resolution and their effects on patient outcomes, this study examines the role of pharmacological treatment in the management of type 2 diabetes. The pathophysiological basis of type 2 diabetes, traditional and modern antidiabetic treatments, factors that contribute to medication non-adherence, techniques for evaluating adherence and the clinical and financial ramifications of poor adherence are all covered in this study. Adverse drug responses, drug-drug interactions, polypharmacy, improper prescribing and medication errors are among the common DRPs that are further examined. Furthermore, a critical evaluation is conducted of pharmacist-led interventions, including pharmaceutical therapy management, patient education, therapeutic counselling, assistance for lifestyle modification, collaborative healthcare practice and telepharmacy. According to available data, pharmaceutical care interventions lower avoidable complications and healthcare utilization while improving medication adherence, glycemic control, drug safety, patient satisfaction and health-related quality of life. Precision pharmacotherapy, artificial intelligence, digital therapies and remote monitoring technologies are examples of emerging developments that present intriguing prospects to improve diabetes care. All things considered, pharmaceutical care continues to be a crucial part of all-encompassing T2DM management and greatly enhances clinical, humanistic and economic outcomes globally....
Pharmacogenomics presents the potential to tailor pharmacotherapy by pinpointing genetic differences linked to responses to medications, adverse effects and treatment efficacy. However, converting pharmacogenomic findings into everyday clinical use entails robust clinical decision-support systems and synchronized healthcare delivery. Pharmacogenomic notifications integrated into electronic health records can relay actionable gene-drug recommendations during prescribing, thus fostering safer and more appropriate drug selection. This review explores the function of pharmacists in the implementation of pharmacogenomic notifications, highlighting their roles in interpreting genetic results, reviewing medications, providing prescribing recommendations, counseling patients and collaborating across professions. Evidence from clinical implementation research suggests that pharmacogenomically informed prescribing can sway therapeutic choices and potentially decrease specific adverse drug reactions. However, clinical advantages vary based on gene-drug associations, implementation strategies, notification designs, clinician acceptance and healthcare environments. Ongoing challenges include a lack of pharmacogenomic knowledge, insufficient interoperability, alert fatigue, financial limitations, ambiguous professional responsibilities and uneven access to testing. Pharmacists can tackle various implementation obstacles through focused education, standardized processes, cooperative practice and systematic evaluation of outcomes. Future studies should determine the comparative effectiveness, cost-efficiency, sustainability and fairness of pharmacist-led services. Incorporating clinically relevant notifications into standard pharmacy practice may enhance precise pharmacotherapy and medication safety, while also promoting evidence-based, patient-centered prescribing across healthcare contexts....
Pharmacogenomics offers an evidence-based approach to individualizing pharmacotherapy by examining how genetic variation influences drug metabolism, transport, target interactions, efficacy and toxicity. Despite advances in precision medicine, conventional prescribing may result in suboptimal therapeutic responses and preventable adverse drug reactions because of interindividual variability. This review critically examines the biological determinants, clinical applications and translational considerations of pharmacogenomics-guided pharmacotherapy. Relevant literature was explored through PubMed/MEDLINE, Scopus, Web of Science, Embase and the Cochrane Library, supplemented by reference-list screening and relevant clinical practice guidelines. Evidence was narratively synthesized to evaluate clinically actionable gene–drug associations, therapeutic outcomes, implementation strategies and existing research gaps. Applications across cardiovascular medicine, oncology, psychiatry, infectious diseases and pain management demonstrate the potential of genotype-informed drug selection, dose individualization and toxicity prevention. Clinical implementation recommendations from established pharmacogenomic resources provide practical guidance for integrating validated genetic findings into prescribing decisions. However, clinical utility varies across gene–drug pairs and depends on evidence strength, test accessibility, result turnaround time, clinical decision-support systems and healthcare infrastructure. Additional challenges include unequal representation of ancestry groups, economic constraints, inconsistent testing practices and limited evidence for certain associations. Effective integration requires collaboration among healthcare professionals, validated testing approaches, interpretable recommendations and continued evaluation of patient outcomes. Pharmacogenomics-guided pharmacotherapy can support safer and more individualized treatment; nevertheless, broader adoption requires stronger prospective evidence, equitable access and sustainable implementation strategies....
Loading....